Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Apyx Medical CorporationNASDAQ: APYX
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables grows, but more slowly than its trailing trend
Q1 FY2026 accounts payables of $411K (cash outflow) rose 24.2% year over year, behind the +34.1% change in trailing-twelve-month accounts payables. Sequentially, it rose 165.2% from the prior quarter. Over 3 fiscal years it compounded at +74.3% a year.
Context
- Accounts payables amounted to 0.7% of revenue in FY2025, up 0.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +24.2% toward the trailing-twelve-month pace of +34.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 355K USD
- Year-over-year change
- +663.5%
- 4-year CAGR
- -25.5%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 355K | +663.5% |
| FY2024 | 2024-12-31 | (63K) | -352.0% |
| FY2023 | 2023-12-31 | 25K | -62.7% |
| FY2022 | 2022-12-31 | 67K | -94.2% |
| FY2021 | 2021-12-31 | 1.15M | — |
Accounts Payables vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 accounts payables of $275K is the 5th largest of the 8 companies compared; the peer median is $83K.
- Its year-over-year change of +34.1% is the 4th highest of 8, against a peer median of -83.9%.
- Accounts payables amounts to 0.5% of revenue for APYX, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.03M | +38.0% | +2.5% | 5.9% | |
| LTM Mar 2026 | $1.37M | -139.9% | +113.5% | 1.9% | |
| LTM Mar 2026 | $586K | +67.9% | — | 0.5% | |
| LTM Mar 2026 | $486K | -114.6% | -55.2% | 0.7% | |
| LTM Mar 2026 | $275K | +34.1% | +74.3% | 0.5% | |
| LTM Mar 2026 | $250K | +278.6% | -15.3% | 4.9% | |
| LTM Mar 2026 | $83K | -83.9% | — | 145.6% | |
| LTM Mar 2026 | $36K | -90.9% | -51.5% | — | |
| Peer median (excluding APYX) | $83K | -83.9% | -15.3% | 3.4% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.